This company listing is no longer active
Epigenomics Balance Sheet Health
Financial Health criteria checks 0/6
Epigenomics has a total shareholder equity of €-8.0M and total debt of €11.9M, which brings its debt-to-equity ratio to -148.3%. Its total assets and total liabilities are €12.8M and €20.9M respectively.
Key information
-148.3%
Debt to equity ratio
€11.89m
Debt
| Interest coverage ratio | n/a |
| Cash | €2.10m |
| Equity | -€8.02m |
| Total liabilities | €20.86m |
| Total assets | €12.84m |
Financial Position Analysis
Short Term Liabilities: ECX has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: ECX has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: ECX has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: ECX's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ECX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ECX has less than a year of cash runway if free cash flow continues to grow at historical rates of 6% each year.